J.C. Lopez

Principal

2020 - Current

Global S&E Lead - Neuroscience, Ophthalmology, and Rare Diseases Partnering

2019 - 2020

Lead the global search, evaluation, and strategy for neuroscience, ophthalmology, and rare diseases for both Roche and Genentech in Roche Pharma Partnering.

Business Development Associate

2018 - 2019

Consultant

2018 - 2018

Business Development MBA Intern

2017 - 2017

Developed comprehensive landscape analysis and business development strategy on the role of artificial intelligence, big data, and multi-omics data in the biopharma space. Conducted diligence screens and term sheet negotiations in areas such as ophthalmology, neuroscience and research platforms. Led cross functional teams composed of internal researchers, in-house legal counsel, and finance team members to execute research collaborations, MTAs and in-licensing deals.

Intern

2016 - 2017

Analyzed the commercial gene therapy landscape that ultimately influenced the firm to pursue a new business venture. Developed the business model for a novel commercial gene therapy entity, which included primary research, market size analysis and financing strategy. Screened pre-clinical technologies on the basis of commercial potential and scientific validity.

Consultant

2017 - 2017

Led a team of six MBAs to execute a pediatric rare disease market sizing and go-to-market strategy for the company's novel WGS analytics platform. Performed a detailed analysis of the clinical genomics decision support market to assess the value proposition provided by WGS versus WES and gene panel arrays. Conducted investigational interviews with KOLs to ascertain the current state of the genomics market as well as identify key areas for novel technology market penetration.

Co Founder

2016 - 2017

Angiio is developing a novel sutureless device to reduce morbidity and mortality associated with open vascular procedures. Current solutions require hand sewing grafts to vessels and are regularly complicated by leakage from suture holes as well as decreased oxygenation to the brain, kidneys, and bowels due to prolonged surgical times. To address this unmet clinical need, Angiio’s sutureless anastomotic device, Vesicon, can deliver superior outcomes via increased integrity of the anastomosis and decreased operative time providing a safer alternative to current treatments.

Program Coordinator Intern

2015 - 2016

Assisted the Center for Health Care Innovation, the Department of Anesthesiology and the Department of Surgery in designing and testing a “virtual” preoperative anesthesia evaluation process via PennChart (Epic). Engaged in contextual inquiry into the current state, further defining the problem, designing experiments and assist developing a solution with minimal supervision. Interacted extensively with patients, surgeons, anesthesiologists and administration within the health system.

Intern

2015 - 2016

Collaborated in the development and implementation of a 20-patient pilot to learn how to engage patients in pre-operative and post-operative behaviors using remote/connected health technology and behavioral science best practices. Communicated with patients via text and phone on a daily basis and partnering with the project team to distill lessons learned and iterate on the pilot on a regular basis.

Fellow, Penn Center for Innovation

2014 - 2015

Assessed the commercial potential of Penn technologies from a technical and intellectual property perspective. Assisted in the licensing of Penn technologies by performing basic market research and developing non-confidential marketing materials for interested investors or strategic partners.

Undergraduate Research Assistant

2011 - 2013

Undergraduate research assistant on the Stanford Accelerated Recovery Trial (START). Performed patient follow up questionnaires. Prepared patient information packets. Enrolled and coordinated patient participation in the START portion of the SNAPL genetics study, which focuses on understanding the genetic basis of pain.